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A B S T R A C T
With the advent of new molecular tools, the discovery of new papillomaviruses (PVs) has accelerated during the
past decade, enabling the expansion of knowledge about the viral populations that inhabit the human body.
Human PVs (HPVs) are etiologically linked to benign or malignant lesions of the skin and mucosa. The detection
of HPV types can vary widely, depending mainly on the methodology and the quality of the biological sample.
Next-generation sequencing is one of the most powerful tools, enabling the discovery of novel viruses in a wide
range of biological material. Here, we report a novel protocol for the detection of known and unknown HPV
types in human skin and oral gargle samples using improved PCR protocols combined with next-generation
sequencing. We identified 105 putative new PV types in addition to 296 known types, thus providing important
information about the viral distribution in the oral cavity and skin.
1. Introduction
Human papillomaviruses (HPVs) are non-enveloped viruses with
double-stranded circular DNA of about 8 kb that can colonize the mu-
cosal and cutaneous epithelia (Bernard et al., 2010; Bzhalava et al.,
2013). To date, more than 200 PVs have been isolated from different
body sites and fully characterized, and this number continues to grow
(Bzhalava et al., 2015; Smelov et al., 2017). Based on the nucleotide
sequences of the major capsid protein L1, HPVs are classified into
genera, species, and types (Bernard et al., 2010). HPV types are orga-
nized into five major genera: alpha, beta, gamma, mu, and nu (de
Villiers et al., 2004). The genera alpha, beta, and gamma include the
majority of the known HPVs. The alpha HPV types have been ex-
tensively studied, because of their clear association with human carci-
nogenesis (Tommasino, 2014). The high-risk (HR) HPV group includes
at least 12 HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
and 59), which are the etiological agents of anogenital cancers and a
subset of head and neck cancers, particularly oropharyngeal cancer
(Bouvard et al., 2009; Haedicke and Iftner, 2013). The genus alpha also
includes the low-risk HPV types (HPV6 and 11) that are associated with
benign genital lesions and with laryngeal disease in children (Giuliano
et al., 2008b; Goon et al., 2008).
The genus beta includes approximately 50 different HPV types, fully
characterized, that are subdivided into five species (beta HPV species
1–5). The majority of the beta HPV types belong to species beta-1 and
beta-2 and are widely present in the skin of healthy individuals. Only 7
HPV types have been classified into the species beta-3 (n=4), beta-4
(n=1), and beta-5 (n=2). HPV types of genus beta can induce warts
and have been associated with certain forms of non-melanoma skin
carcinoma (NMSC) (Orth, 2006). The first beta HPVs, HPV5 and 8, were
isolated from the skin of patients with epidermodysplasia verruciformis
(EV), a rare autosomal recessive hereditary skin disorder that confers
high susceptibility to beta HPV infection and cutaneous squamous cell
carcinoma development at sun-exposed regions (Pfister, 2003). Several
studies showed that beta HPV types are associated with NMSC devel-
opment in non-EV individuals (Andersson et al., 2008; Berkhout et al.,
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2000; Bouwes Bavinck et al., 2010; Casabonne et al., 2007; Cornet
et al., 2012; de Jong-Tieben et al., 1995; Harwood et al., 2000;
Iannacone et al., 2014; Iftner et al., 2003; Karagas et al., 2006;
Waterboer et al., 2008). Patients with a history of NMSC show elevated
positivity for markers of beta HPV infection compared with healthy
individuals (Ally et al., 2013; Asgari et al., 2008; Iannacone et al.,
2012). Recent studies reported the presence of beta HPV types at ad-
ditional anatomical sites other than the skin, such as the oral mucosal
epithelium, eyebrow hairs, penile and external genital samples, and the
anal canal (Arroyo et al., 2013; Barzon et al., 2011; Donà et al., 2016;
Pierce Campbell et al., 2016; Smelov et al., 2017).
Species beta-3 HPV types appear to have a dual tropism, being
present in the skin and the mucosal epithelia (Forslund et al., 2013;
Hampras et al., 2017). Interestingly, studies in in vitro and in vivo ex-
perimental models have highlighted some biological similarities be-
tween beta-3 HPV and mucosal HR HPV types (Cornet et al., 2012;
Viarisio et al., 2016). In addition, Viarisio et al. (2016) showed that
beta-3-HPV49 transgenic mice were highly susceptible to upper diges-
tive tract carcinogenesis upon initiation with 4-nitroquinoline 1-oxide.
HPVs from the gamma, mu, and nu genera induce cutaneous pa-
pillomas or warts (de Villiers et al., 2004) and have been poorly in-
vestigated so far. To date, approximately 80 different gamma HPV types
have been isolated from the skin and genital tract (retrieved from
GenBank, September 2017).
In addition to the fully characterized HPV types, a substantial
number of partial genomic sequences of putative novel HPV types have
been deposited to GenBank, indicating that many more HPV types exist.
So far, the molecular biology techniques for the isolation of novel HPV
types have been based mainly on the use of degenerate and/or con-
sensus primers, followed by cloning and Sanger sequencing (Chouhy
et al., 2010; Forslund et al., 1999). However, considering the large
number of recently characterized HPV genomes, degenerate primers
may be improved in order to discover novel HPV types. In particular,
this strategy may lead to the expansion of species that so far include a
very small number of HPV types, such as species beta-3 (n=4), beta-4
(n=1), and beta-5 (n=2).
In this study, we used novel and well-validated consensus and de-
generate primers to amplify genomic HPV sequences from human DNA
isolated from oral and skin specimens. Analysis of the PCR products by
next-generation sequencing (NGS) resulted in the identification of 105
putative new PV types.
2. Materials and methods
2.1. Sample collection and DNA extraction
Skin swabs and oral rinses from two different ongoing studies
aiming to determine the prevalence of viral DNA and its associations
with disease were used in the present analysis (Hampras et al., 2014,
2015; Nunes et al., 2016; Pierce Campbell et al., 2013, 2016).
Skin swab specimens (n=119) were randomly selected from the
VIRUSCAN Study, an ongoing five-year (2014–2019) prospective co-
hort study conducted at Moffitt Cancer Center and the University of
South Florida (R01CA177586-01; “Prospective study of cutaneous viral
infections and non-melanoma skin cancer”). An area of approximately
5× 5 cm of the top of the sun-exposed forearm was sprayed with 0.9%
saline solution. A cotton-tipped Dacron swab (Digene, Gaithersburg,
MD, USA) was then rubbed back and forth a few times to collect ex-
foliated skin cells. Individual swabs were placed in a separate vial and
preserved in Digene Standard Transport Medium.
In addition, 62 oral rinses were randomly selected from the HPV
Infection in Men (HIM) study, a large, multinational (Brazil, Mexico,
and the USA) prospective cohort study of the natural history of HPV
infection in men. The HIM study methods have previously been de-
scribed in detail (Giuliano et al., 2008a, 2009, 2011; Nyitray et al.,
2011). A further 85 oral samples were selected from a pilot study that
aimed to estimate the prevalence of Helicobacter pylori in oral gargles
from a Latvian population. The study was approved (No. 8-A/15) by the
Ethics Committee of Riga East University Hospital Support Foundation.
After DNA extraction, all samples were analyzed at the International
Agency for Research on Cancer (Lyon, France) for viral DNA from HPV.
2.2. PCR protocols
The following PCR protocols using different sets of primers were run
(Table 1): (i) CUT primers, as previously described (Chouhy et al.,
2010); (ii) FA-type (FAP) primers, as previously described (Forslund
et al., 1999); (iii) a new set of FAP primers, i.e. FAP59.1, FAP59.2, and
FAP64.1 (Fig. 1; Table 1); these primers were used to generate two
different primer mixtures (FAPM1 and FAPM2); the PCR conditions
were the same as for the original FAP protocol; (iv) a set of 11 beta-3
specific primers (henceforth referred to as beta-3-1) (Table 1); and (v) a
set of 4 broad-spectrum beta-3 degenerate primers (henceforth referred
to as beta-3-2). The beta-3-1 and beta-3-2 primers were synthesized by
MWG Biotech (Ebersberg, Germany) and mixed to obtain a 10× solu-
tion containing 2 µM of each primer. PCR was performed with the
Qiagen Multiplex PCR kit (Hilden, Germany) according to the manu-
facturer's instructions. The use of these primers enables the amplifica-
tion of a region in the L1 gene of approximately 450 bp.
2.3. Validation of the new set of primers
To evaluate the sensitivity of the novel HPV PCR protocols (beta-3-
1, beta-3-2, FAPM1, and FAPM2), we used an artificial mixture con-
taining cloned HPV genomes at different relative concentrations (10-
Table 1
Sequences of the oligonucleotides and composition of the different protocols.
i= inosine; W = A or T; D = A or G or T; K = T or G; Y = C or T; M = A or C;
R = A or G; V = A or C or G; H = A or C or T.
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Fig. 1. Construction of improved FAP degenerate primers by alignment of 46 beta HPV type L1 regions with MUSCLE 3.8.
R.N. Brancaccio et al. Virology 520 (2018) 1–10
3
fold dilution series starting from 10,000 to 0 copies of the viral genome)
and mixed with human genomic DNA. PCR products were analyzed by
electrophoresis on a 2% agarose gel.
2.4. NGS analysis
The PCR products were purified on a 2% agarose gel using the
QIAquick gel extraction kit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. One additional purification step was per-
formed to remove any remaining contaminants using the Agencourt
AMPure XP PCR purification kit with a beads ratio of 1.8× (Beckman
Coulter). Purified PCR products were divided into eight different pools.
Each pool included approximately 50 different amplicons generated
from different PCR protocols (Table 2).
Libraries were prepared using the Nextera XT DNA Library pre-
paration kit (Illumina, San Diego, CA, USA). Illumina MiSeq dual-in-
dexed adapters (Illumina, San Diego, CA, USA) were added to each of
the PCR pools.
NGS was performed using the Illumina MiSeq kit v3 (600 cycles) on
the Illumina MiSeq system. In order to enrich the diversity of the li-
braries, 10% of PhiX (Illumina, San Diego, California, USA) was added
to the NGS reaction.
2.5. Bioinformatics analysis
Quality control was conducted using FastQC (Andrews, 2010)
(v0.11.5) and MultiQC (Käller and Ewels, 2016) (v1.0). Trim Galore
(v0.4.4) (Krueger, 2015) was used to remove remaining adapter se-
quences and trim low-quality ends of reads. The merging of forward
and reverse reads, the de-replication step, the de novo chimeric se-
quence identification, and the clustering steps were carried out using
VSEARCH (Mahé and Rognes, 2016) (v2.4.0). MegaBlast in the Blast
package (v2.6.0+) (Altschul et al., 1990) was launched against the
nucleotide collection (nr/nt, March 2017) database in a local server to
enable the identification of the previously constructed clusters.
Another level of clustering was applied for the reads having the
same best MegaBlast results inside each pool (based on the E-value).
Each cluster of reads was then processed using the CAP3 program in
order to assemble contigs (Huang and Madan, 1999).
A reference species phylogenetic tree was constructed based on the
full-L1 ORF nucleotide sequences of 458 available PV genomes re-
trieved from the PaVE database (https://pave.niaid.nih.gov/) (Van
Doorslaer et al., 2013) in January 2018. The sequences were aligned at
the nucleotide level using the MUSCLE algorithm, with the default
parameters (Edgar, 2004), in MEGA7 (Kumar et al., 2016). The final
full-length L1-ORF alignment encompassed 458 full L1-ORF nucleotide
sequences, 2259 positions, and 627 distinct alignment patterns. MEGA7
was used to test the best substitution model and for the phylogenetic
inference. The codon positions included were 1st+ 2nd+3rd+non-
coding. Based on the alignment using MUSCLE, all positions with<
95% site coverage were eliminated (partial deletions), to enable the
inclusion of taxa with some missing data. There was a total of 1383
positions in the final dataset.
A discrete gamma distribution was used to model evolutionary rate
differences among sites (five categories; +G, parameter = 1.0326).
The rate variation model allowed for some sites to be evolutionarily
invariable ([+I], 2.5307% sites).
The initial trees for the heuristic search were obtained automatically
by applying the neighbor-joining (NJ)/BioNJ algorithm to a matrix of
pairwise distances estimated using the maximum composite likelihood
(MCL) approach and then by selecting the topology with the highest log
likelihood value (−389774.5274).
Phylogenetic inference was performed with MEGA7 using the gen-
eral time reversible (GTR) model of nucleotide substitution and 500
bootstrap replicates (Nei and Kumar, 2000).
PaPaRa (v2.5) (Berger and Stamatakis, 2011) was used to align the
sequences reconstructed using the CAP3 algorithm with respect to the
reference multiple sequence alignment. Subsequently, the evolutionary
placement algorithm (EPA) in RAxML (v8.2.11) (Berger et al., 2011;
Stamatakis, 2014) was run to place the sequences into the reference
species phylogenetic tree. The EPA was run using the same nucleotide
substitution model used to infer the reference phylogenetic tree. A
script was developed in-house to parse the output format (Matsen et al.,
2012) of the EPA.
In addition, a blastn local alignment query of the contigs was used
to align them against a comprehensive database of reference PVs pre-
sent in the PaVE database (n= 330 genomes). This approach mimics
locally the L1 taxonomic tool of the PaVE database.
All the results in this study are based on the identification of the
sequences using the EPA in RAxML (henceforth referred to as RAxML-
EPA). Only the longest sequence was considered for RAxML-EPA clas-
sification when several singlets or contigs were available. Krona (Ondov
et al., 2011) was used for the graphical representation of the data.
3. Results
3.1. Design and validation of novel HPV PCR primers
As a first step, we generated new consensus primers considering all
known beta HPV types. HPV beta-3 species primers were designed by
aligning the L1 open reading frame (ORF) from all four beta-3 HPV
types (HPV49, 75, 76, and 115) using the ClustalW2 multiple sequence
alignment tool (Chenna et al., 2003). Two different sets of primers were
generated: (i) a set of 11 specific primers, termed beta-3-1, and (ii) a set
of 4 degenerate primers, termed beta-3-2. The composition of the two
primer mixtures is shown in Table 1.
As a second approach, we generated additional degenerate primers
based on the well-validated FAP primers (Forslund et al., 1999). The
FAP primers were developed in 1999 by aligning 77 L1 ORF sequences
from different genera that included at that time only a limited number
of beta (n=22) and gamma (n=5) HPV type sequences, obtained
from the 1996 and 1997 HPV Sequence Database Compendia (Myers
et al., 1996, 1997).
Forty-six L1 sequences representative of the beta HPV types known
to date (Van Doorslaer et al., 2017) were aligned against FAP primer
sequences, using the MUSCLE (3.8) multiple sequence alignment tool
(Edgar, 2004). Subsequently, three improved broad-spectrum FAP pri-
mers, with an increased specificity for beta HPV types, were generated
(Fig. 1): FAP59.1, FAP59.2, and FAP64.1. These were mixed in different
combinations, generating two different mixtures: FAPM1 and FAPM2
(Table 1). The beta-3 protocol enabled the detection of beta-3 HPVs
with a limit of detection of 10 copies. The detection limit using the
FAPM1 mixture was 10 copies for HPV types that belong to species
beta-2, beta-3, and beta-4 and 1000 copies for beta-5. Using the FAPM2
protocol, the detection limit was 10 copies for HPV types that belong to
Table 2
Description of the PCR protocols and NGS pools.
PCR pools PCR protocols Specimens N NGS pools
1 Beta-3-1 Skin swab 41 1
2 Beta-3-2 9
3 FAP 52 2
4 FAPM1 54 3
5 CUT 57 4
6 FAPM2 Oral gargle 43 5
7 FAPM1 56 6
8 CUT 55 7
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beta-3, beta-4, and beta-5; however, a lower sensitivity was observed
for species beta-2 (10,000 copies) (data not shown).
3.2. NGS data analysis: characterization and taxonomic classification
Randomly selected DNA extracted from skin swabs (n=119) and
oral gargles (n=147) obtained from healthy individuals was amplified
using the PCR protocols described above and the original FAP and CUT
protocols (Table 2) (Chouhy et al., 2010; Forslund et al., 1999). PCR
products were mixed to obtain 8 different pools (Table 2) and se-
quenced using the Illumina MiSeq sequencing platform.
A total of 50,017,076 paired-end raw reads were obtained from the
NGS analysis. After quality trimming, de-replication, and chimeric PCR
sequence removal, 47.3% (23,647,656) of the reads were considered for
further analysis. Approximately 67% (16,043,298 reads) were related
to PV sequences. Each read was matched against National Center for
Biotechnology Information (NCBI) database sequences (nr/nt, March
2017) using the MegaBlast algorithm and assigned to its closest PV
type, before contig construction.
Analysis of the data with RAxML-EPA revealed that the reads gen-
erated from the sequencing of the 119 skin DNA samples were assigned
to a total of 265 different PV types (Fig. 2A; Table S1), which belong
mainly to the alpha (33.4%) and beta (29.5%) genera, thus representing
the PV distribution in skin. In addition, a substantial fraction of reads
(12.9%) was assigned to taxonomically unclassified PV sequences
(hereafter called “unclassified PVs”): bovine papillomavirus type 19
(BPV19), equine papillomavirus type 8 (EcPV8), Myotis ricketti pa-
pillomavirus 1 (MrPV1), Pudu puda papillomavirus type 1 (PpuPV1),
and Sparus aurata papillomavirus type 1 (SaPV1). Moreover, 9% of the
reads were assigned to the gamma genus.
The FAPM1 protocol enabled the detection of 107 PVs (8 alpha, 37
beta, 60 gamma, and 2 mu), and the CUT and FAP protocols enabled
the detection of 118 PVs (11 alpha, 36 beta, 68 gamma, 2 mu, and 1 nu)
and 87 PVs (3 alpha, 34 beta, 49 gamma, and 1 mu), respectively. The
combined beta-3-1 and beta-3-2 protocols generated a majority of reads
assigned to a non-human alpha PV type: Colobus guereza monkey pa-
pillomavirus type 1 (CgPV1). Two reads were assigned to HPV16. Five
beta HPVs were detected using these combined protocols (797,800
reads), of which 3 were assigned to species beta-3. Only 2 non-refer-
enced gamma HPV types were detected (HPV-mDysk1 – KX781280 and
HPV-mDysk6 – KX781285).
The reads generated from the sequencing of the 147 oral DNA
samples were assigned to a total of 161 different PV types. PV types that
belong to the genus beta were most common (29.5%), followed by
genus gamma (19.6%) and genus alpha (7.8%) (Fig. 2B; Table S2). In
addition, a substantial fraction of reads (36.9%) was assigned to tax-
onomically unclassified PVs: EcPV8, Miniopterus schreibersii papilloma-
virus type 1 (MscPV1), PpuPV1, and SaPV1 (Fig. 2B; Table S2).
The FAPM1 and FAPM2 protocols enabled the detection of 55 PVs
(4 alpha, 30 beta, and 21 gamma) and 42 PVs (5 alpha, 21 beta, and
16 gamma), respectively. Forty-six PVs (6 alpha, 17 beta, and
23 gamma) were detected using the CUT protocol (Fig. 2B; Table S2).
Substantial numbers of reads identified in both skin (745,860 reads)
and oral (163,448 reads) samples were related to taxonomically clas-
sified non-human PVs (i.e. PVs not belonging to the genera alpha, beta,
gamma, mu, and nu) (Tables S1 and S2; Fig. 2).
3.3. Subdivision of the NGS reads into known and putative novel PVs
The NGS sequences were divided into two groups, on the basis of the
initial MegaBlast results: (i) L1 sequences with ≥ 90% similarity with a
known PV (i.e. known PV types) and (ii) L1 sequences with< 90%
similarity with any known PV (i.e. putative novel PV types). This sub-
division was followed by contig construction and sequences identifi-
cation using CAP3 and RAxML-EPA, respectively.
Regarding the sequences that share ≥ 90% of identity with known
PVs, a total of 8,002,617 reads were generated. The majority were from
the genus beta (2,358,670 reads), followed by alpha (1,992,264 reads)
and gamma (1,002,061 reads) (Fig. 3A). A substantial proportion of the
reads (1,678,061 reads) was assigned to the “unclassified PVs” cate-
gory, mainly represented by SaPV1 (KX643372.1). The beta-3-1 and
beta-3-2 protocols generated a total of 2,588,649 reads (pool 1,
Table 2), with a majority (56.6%) of alpha PV sequences, followed by
beta HPV sequences (30.8%) (Fig. 3A). The FAP protocol (pool 2)
generated 985,675 reads in skin samples, of which 40.8% belonged to
the genus beta and 14.5% to gamma (Table 2; Fig. 3A). The FAPM1
protocol (pool 3) enabled the detection in skin samples of 861,810
reads, comprising alpha (23.3%), beta (13.6%), gamma (14.3%), and
mu (7.6%) PV-related sequences (Table 2; Fig. 3A). In oral samples
(pool 6), when the same PCR protocol was used, generating 244,587
reads, a different distribution of alpha, beta, and gamma PVs was ob-
served, with 0.1%, 53.6%, and 12.3%, respectively (Table 2; Fig. 3A).
The use of the CUT protocol on skin samples (pool 4) generated
884,923 reads, from the alpha (13%), beta (19.5%), and gamma
(23.3%) genera. When the same protocol was used on oral samples
(pool 7), generating 78,060 reads, the proportion of alpha (2.1%), beta
(11%), and gamma (17.2%) PV-related sequences was different
(Table 2; Fig. 3A). The highest proportion of reads (43.4%) generated
from this pool corresponded to an unclassified PV (SaPV1).
The FAPM2 protocol (pool 5), used in oral samples, generated
466,004 reads, with a distribution of 9.3% alpha, 39.6% beta, and
32.5% gamma PV-related sequences (Table 2; Fig. 3A).
In addition, products from five PCR protocols (pool 8, Table 2) were
pooled and analyzed by NGS. This pool generated 1,892,909 reads, of
which 24.5% were representative of beta, 8.8% alpha, and 17.6%
gamma PVs. The highest proportion of reads (44.3%) was re-
presentative of unclassified PVs (Tables S2).
All the reads correspond to 296 known PV types, including 30 alpha
PVs, of which 14 were found in skin samples, 8 in oral samples, and 8 in
both tissues. Fifty-four beta HPVs were identified, of which 13 were
from the skin, 3 from the oral cavity, and 38 from both tissues.
Regarding the genus gamma, 123 known HPVs were identified, of
which 70 were isolated from the skin, 8 from the oral cavity, and 45
from both anatomical sites. Three mu HPVs were found (1 in the skin
and 2 in both skin and oral samples), and only 1 nu HPV was found (in
the skin). Six unclassified PV types were identified, of which 2 were
isolated from the skin, 1 from the oral cavity, and 3 from both sites
(data not shown).
In addition, 11.3% of the reads (n=909,308) corresponded to 79
sequences of diverse PVs that do not belong to any of the five PV genera
(alpha, beta, gamma, mu, and nu) that contain HPVs; 34 of these 79
sequences were isolated from the skin, 11 from the oral cavity, and 34
from both sites (data not shown).
Regarding the putative novel PVs, we identified 19,032 reads
with< 90% similarity with known PVs. The majority of these reads
were related to beta (35.6%) and gamma (23.2%) HPV types (Fig. 3B;
Table S3). The beta-3-1 and beta-3-2 protocols enabled the identifica-
tion in pool 1 of 22 reads (26.8%) that are representative of 2 putative
new beta-3-related sequences (Fig. 3B; Table S3). In the same pool, 54
reads (65.8%) were assigned to an unclassified PV. However, in the
same cluster, a smaller contig was assigned to Psipapillomavirus (Table
S3). The remaining reads (n=6, 7.3%) were assigned to Dyophipa-
pillomavirus 1, but were matched against HPV115 using the PaVE
classification. The FAP protocol enabled the detection in pool 2 of pu-
tative new beta (40 reads, 1.2%) and gamma (2228 reads, 69.2%) HPV
types. Of the 116 reads that were assigned to unclassified PV using
RAxML-EPA, 2 were related to HPV MTS2 (gamma-7) according to the
PaVE classification (Dutta et al., 2017). Finally, 833 reads were iden-
tified as Taupapillomavirus 3, 4 reads as Deltapapillomavirus 5, and 3
reads as Dyorhopapillomavirus 1 (Table S3).
The FAPM1 protocol enabled the detection in pool 3 of sequences
representative of putative new beta (294 reads, 70.2%), gamma (48
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Fig. 2. Graphical representation of the unnormalized abundance of PV genera and species in terms of number of reads: (A) skin samples, (B) oral samples.
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reads, 11.5%), delta-2 (52 reads, 12.4%), and lambda-3 (7 reads, 1.7%)
PV types. In oral samples, the same protocol enabled the identification
of 21 reads, of which 9.5% were found to be related to putative new
beta-1 HPV types, 23.8% to Sigmapapillomavirus 1, and 66.7% to
Dyoiotapapillomavirus 2 using RAxML-EPA (Fig. 3B; Table S3). No pu-
tative new gamma HPV types were identified.
The use of the CUT protocol on skin samples (pool 4) revealed
the presence of 2126 reads (72.7%) representative of putative new
gamma HPV types. A smaller fraction (4.2%) was representative of
putative new beta HPV types. This protocol also revealed the presence
of 12 nu and 12 alpha (assigned to species alpha-2 and alpha-3) PV-
related reads. RAxML-EPA indicated that 2 reads corresponded to
Lambdapapillomavirus 3, whereas the same reads got their best initial
MegaBlast match against canine papillomavirus 6 (CPV6). Eight other
putative non-human PVs were also found (Table S3).
In oral samples (pool 5), when the FAPM2 protocol was used, 6295
reads (99.9%) were representative of putative new beta HPV types, and
0.1% were representative of putative new gamma HPV types (Fig. 3B;
Table S3). The CUT protocol (pool 7) enabled the identification in oral
samples of only one putative new non-human PV (Chipapapillomavirus
2), as well as an unclassified type using RAxML-EPA, but all such reads
were assigned to species beta-1 using the PaVE database (Table S3).
Regarding pool 8, only 0.07% and 0.3% of the reads were assigned
to beta and mu HPVs, respectively. The remaining reads were related to
an unclassified PV (3308 reads), to Treisdeltapapillomavirus 1 (2713
reads), and to other non-human PV genera (Treisepsilonpapillomavirus,
Treisdeltapapillomavirus, and Treiszetapapilloamvirus; 16 reads).
In summary, all the reads corresponded to 105 putative novel PV
types, including 29 beta HPVs, of which 21 were found in skin and 8 in
oral samples. Thirty-two gamma HPV types were identified, of which
30 were found in skin and 2 in oral samples. Only 2 putative new alpha
HPVs were found in the skin. One mu HPV was found in skin samples.
Twenty-four diverse PVs that do not belong to any of the five PV genera
that contain HPVs were identified, of which 17 were found in skin and 7
in oral samples. Moreover, 17 unclassified PVs were isolated from skin
(n=15) and oral (n=2) samples. However, these reads were found to
correspond to beta (n=9) and gamma (n=8) HPVs when the PaVE
algorithm was used.
4. Discussion
Since the discovery of the first HPV type four decades ago (Orth
et al., 1978), 127 alpha, 93 beta, and 135 gamma HPVs have been
described in the Papillomavirus Episteme database (Van Doorslaer
et al., 2017). Alpha, beta, and gamma are the most representative
genera (Doorbar et al., 2012).
To identify new HPV types, FAP and CUT primers combined with
cloning and Sanger sequencing-based strategies have been used suc-
cessfully in the past (Chouhy et al., 2010; Forslund et al., 1999).
However, this approach is quite laborious and time-consuming, and
Fig. 3. (A) Distribution of the known PVs detected in the different NGS pools, in terms of percentage of reads within each pool; (B) distribution of the putative new
PVs detected in the different NGS pools, in terms of percentage of reads within each pool (RAxML-EPA).
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enables the identification of the most represented amplicons only. In
particular, this strategy is ineffective in the context of multiple infec-
tions. With the advent of new molecular tools (e.g. NGS), the discovery
of new HPVs has accelerated over the past few years (Bzhalava et al.,
2014; Kocjan et al., 2015). Several studies have shown the capability of
NGS in detecting low-copy HPV infections, especially in multiple in-
fections (Arroyo et al., 2013; Barzon et al., 2011; Ekström et al., 2011;
Johansson et al., 2013).
Here, we developed a strategy that combines the use of specific or
degenerate primers targeting the L1 region of a broad spectrum of HPVs
with NGS, for the detection of new HPV types, especially from the genus
beta. This strategy incorporates the selective enrichment of PV se-
quences before NGS is performed. Approximately two thirds of the
reads were related to PV sequences. Similar approaches have been re-
ported previously (Arroyo Mühr et al., 2015; Ekström et al., 2013,
2011).
The growing interest in the beta genus arises from evidence that a
number of beta HPV types may be involved in pre-malignant and ma-
lignant skin lesions (Pfister et al., 2003; Tommasino, 2017). Interest-
ingly, species beta-3 HPV types have been detected in the skin and
mucosal epithelia (Forslund et al., 2013; Hampras et al., 2017). Func-
tional studies in in vitro and in vivo experimental models have high-
lighted some biological similarities between beta-3 and mucosal HR
HPV types. HPV49 shows transforming activity in primary human
keratinocytes, and shares some features with HPV16 (Cornet et al.,
2012; Viarisio et al., 2016). One of our objectives was to expand the
biologically relevant species beta-3, which includes only 4 HPV types,
by using beta-3 consensus and degenerate primers.
Combining PCR with novel sets of HPV primers and NGS, we
showed the presence of a total of 105 putative new PVs. This procedure
also demonstrated the presence of 296 known PV types. Our study
showed the presence of a substantial number of beta and gamma HPV
types in the oral cavity, which supports the hypothesis of a possible
mucosal tropism. However, environmental contamination of the oral
cavity cannot be excluded. Furthermore, several other sequences re-
lated to unclassified and non-human PVs were identified in skin and
oral samples. Environmental contamination may explain the presence
of non-human PVs in skin and oral samples. However, cross-species
transmission of PVs between animals and humans may also be a con-
sideration (Bravo and Félez-Sánchez, 2015; Gottschling et al., 2011),
even though PVs are typically considered to be highly host-restricted
(with a few exceptions). Sequences related to bovine PVs have been
found in horses and other equids, suggesting interspecies transmission
events (Lunardi et al., 2013; Trewby et al., 2014). Other studies also
reported cases of cross-species transmission of PVs between bat species
(García-Pérez et al., 2014), between rhesus and cynomolgus macaques
(Chen et al., 2009), and between humans and cats (Anis et al., 2010;
O’Neill et al., 2011); however, additional studies are needed to confirm
the latter.
In addition, the notion of “non-human” PV genera needs to be in-
terpreted with caution as they may also include some HPVs. Similarly,
alpha and beta genera include few non-human primate PVs (Bernard
et al., 2010; Rector and Van Ranst, 2013).
All the results in this study are based on the identification of the
sequences using the RAxML-EPA classification. A total of 105 putative
new PVs (including 29 beta, 32 gamma, 2 alpha, and 1 mu PVs) were
found. In addition, 24 diverse PVs that do not belong to any of the five
PV genera that contain HPVs were identified. Interestingly, 17 of the
105 putative new PVs (16.2%) were assigned to taxonomically un-
classified PVs. These PVs may not belong to any of the known genera
that contain human or animal PVs, and thus may be representative of
putative new genera.
The taxonomic assignment performed in this study must be inter-
preted cautiously, because only small portions of putative new PV
genomes have been obtained. In addition, the results obtained using the
blastn algorithm refer exclusively to the fraction of the sequence that is
aligned by the algorithm. The percentage of similarity indicated by the
initial MegaBlast results must also be interpreted with caution, because
the definition of novelty for a PV is based on the full L1 ORF length.
In this study, the different protocols were run on different human
specimens, and showed different efficacies in detecting putative new
PVs, as well as known PVs. The beta-3-1 and beta-3-2 protocols enabled
the identification of 4 new beta-3-related sequences in skin samples
(using the RAxML-EPA classification), which may potentially expand
the beta-3 group to 8 PV types. In vitro experiments are needed to
provide insight into the biological properties of these PV types, and to
investigate whether these types share biological features with HPV49
(Cornet et al., 2012; Viarisio et al., 2016). The CUT primers enabled the
detection of a broad range of PV types in skin and oral samples, in-
cluding alpha PV types, as previously reported (Chouhy et al., 2010). In
contrast, the original FAP protocol was much less likely to identify PVs
belonging to the genus alpha. The FAPM1 and FAPM2 protocols en-
abled the detection of the largest number of putative new PVs in oral
samples, whereas the CUT primers enabled the detection of the largest
number of putative new PVs in skin samples. Interestingly, the FAPM1
and CUT protocols showed good performance in the detection in skin
samples of new PV types that belong to non-human PV genera.
Together, the different protocols enabled the identification of a
substantial number (n= 62) of putative new beta and gamma HPV
types, as well as putative non-human PVs (n= 24), in both skin and
oral samples.
The gamma HPV types constitute a large group of HPVs that are not
yet clearly associated with human disease. However, HPV197, a
member of species gamma-24, has recently been detected in human
skin cancer specimens (Arroyo Mühr et al., 2015; Grace and Munger,
2017). To date, only 3 HPV types have been classified into the species
gamma-24. The use of consensus or degenerate gamma-24 primers
might facilitate the discovery of new related PV types, if any exist. Some
of the putative new beta or gamma HPV types may also show trans-
forming activity.
In summary, the present study describes a robust strategy based on
the use of specific or degenerate primers and NGS technology to detect
putative novel PVs. Although the identification of novel PV types or
species can only be definitively confirmed by sequencing the whole L1
ORF, initial studies have confirmed the validity of our new protocol as a
first step for the isolation and full characterization of novel HPV gen-
omes (e.g. HPV ICB1) (Brancaccio et al., 2017).
The discovery of novel HPV types remains of paramount im-
portance, because new associations between HPV infections and human
diseases may be established.
Acknowledgments
We are grateful to Dr. Karen Müller and Jessica Cox for editing. This
study was supported in part by the European Commission project HPV-
AHEAD (FP7-HEALTH-2011-282562), by the grant VIRUSCAN R01 (no.
R01CA177586-01), and by a grant from “Fondation ARC” (no. PJA
20151203192).
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.virol.2018.04.017.
References
Ally, M.S., Tang, J.Y., Arron, S.T., 2013. Cutaneous human papillomavirus infection and
basal cell carcinoma of the skin. J. Investig. Dermatol. 133. http://dx.doi.org/10.
1038/jid.2013.46.
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J., 1990. Basic local alignment
search tool. J. Mol. Biol. 215, 403–410. http://dx.doi.org/10.1016/S0022-2836(05)
80360-2.
Andersson, K., Waterboer, T., Kirnbauer, R., Slupetzky, K., Iftner, T., de Villiers, E.-M.,
R.N. Brancaccio et al. Virology 520 (2018) 1–10
8
Forslund, O., Pawlita, M., Dillner, J., 2008. Seroreactivity to cutaneous human pa-
pillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions.
Cancer Epidemiol. Biomark. Prev. 17, 189–195. http://dx.doi.org/10.1158/1055-
9965.EPI-07-0405.
Andrews,S., 2010. FastQC: a quality control tool for high throughput sequence data.
Anis, E.A., O’Neill, S.H., Newkirk, K.M., Brahmbhatt, R.A., Abd-Eldaim, M., Frank, L.A.,
Kania, S.A., 2010. Molecular characterization of the L1 gene of papillomaviruses in
epithelial lesions of cats and comparative analysis with corresponding gene se-
quences of human and feline papillomaviruses. Am. J. Vet. Res. 71, 1457–1461.
http://dx.doi.org/10.2460/ajvr.71.12.1457.
Arroyo, L.S., Smelov, V., Bzhalava, D., Eklund, C., Hultin, E., Dillner, J., 2013. Next
generation sequencing for human papillomavirus genotyping. J. Clin. Virol. 58,
437–442. http://dx.doi.org/10.1016/j.jcv.2013.07.013.
Arroyo Mühr, L.S., Hultin, E., Bzhalava, D., Eklund, C., Lagheden, C., Ekström, J.,
Johansson, H., Forslund, O., Dillner, J., 2015. Human papillomavirus type 197 is
commonly present in skin tumors. Int. J. Cancer 136, 2546–2555. http://dx.doi.org/
10.1002/ijc.29325.
Asgari, M.M., Kiviat, N.B., Critchlow, C.W., Stern, J.E., Argenyi, Z.B., Raugi, G.J., Berg,
D., Odland, P.B., Hawes, S.E., de Villiers, E.-M., 2008. Detection of human papillo-
mavirus DNA in cutaneous squamous cell carcinoma among immunocompetent in-
dividuals. J. Investig. Dermatol. 128, 1409–1417. http://dx.doi.org/10.1038/sj.jid.
5701227.
Barzon, L., Militello, V., Lavezzo, E., Franchin, E., Peta, E., Squarzon, L., Trevisan, M.,
Pagni, S., Dal Bello, F., Toppo, S., Palù, G., 2011. Human papillomavirus genotyping
by 454 next generation sequencing technology. J. Clin. Virol. 52, 93–97. http://dx.
doi.org/10.1016/j.jcv.2011.07.006.
Berger, S.A., Krompass, D., Stamatakis, A., 2011. Performance, accuracy, and Web server
for evolutionary placement of short sequence reads under maximum likelihood. Syst.
Biol. 60, 291–302. http://dx.doi.org/10.1093/sysbio/syr010.
Berger, S.A., Stamatakis, A., 2011. Aligning short reads to reference alignments and trees
(https://doi.org/). Bioinformatics 27, 2068–2075. http://dx.doi.org/10.1093/
bioinformatics/btr320.
Berkhout, R.J., Bouwes Bavinck, J.N., ter Schegget, J., 2000. Persistence of human pa-
pillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant
recipients. J. Clin. Microbiol. 38, 2087–2096.
Bernard, H.-U., Burk, R.D., Chen, Z., van Doorslaer, K., zur Hausen, H., de Villiers, E.-M.,
2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of
taxonomic amendments. Virology 401, 70–79. http://dx.doi.org/10.1016/j.virol.
2010.02.002.
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F., Benbrahim-
Tallaa, L., Guha, N., Freeman, C., Galichet, L., Cogliano, V., WHO International
Agency for Research on Cancer Monograph Working Group, 2009. A review of human
carcinogens–Part B: biological agents. Lancet Oncol. 10, 321–322.
Bouwes Bavinck, J.N., Neale, R.E., Abeni, D., Euvrard, S., Green, A.C., Harwood, C.A., de
Koning, M.N.C., Naldi, L., Nindl, I., Pawlita, M., Pfister, H., Proby, C.M., Quint,
W.G.V., ter Schegget, J., Waterboer, T., Weissenborn, S., Feltkamp, M.C.W., EPI-HPV-
UV-CA group, 2010. Multicenter study of the association between betapapillomavirus
infection and cutaneous squamous cell carcinoma. Cancer Res. 70, 9777–9786.
http://dx.doi.org/10.1158/0008-5472.CAN-10-0352.
Brancaccio, R.N., Robitaille, A., Dutta, S., Rollison, D.E., Fischer, N., Grundhoff, A.,
Tommasino, M., Gheit, T., 2017. Complete genome sequence of a novel human
gammapapillomavirus isolated from skin. Genome Announc. 5. http://dx.doi.org/10.
1128/genomeA.00833-17.
Bravo, I.G., Félez-Sánchez, M., 2015. Papillomaviruses: viral evolution, cancer and evo-
lutionary medicine. Evol. Med. Public Health 2015, 32–51. http://dx.doi.org/10.
1093/emph/eov003.
Bzhalava, D., Eklund, C., Dillner, J., 2015. International standardization and classification
of human papillomavirus types. Virology 476, 341–344. http://dx.doi.org/10.1016/j.
virol.2014.12.028.
Bzhalava, D., Guan, P., Franceschi, S., Dillner, J., Clifford, G., 2013. A systematic review
of the prevalence of mucosal and cutaneous human papillomavirus types. Virol. Spec.
Issue.: Papillomavirus Epistem. 445, 224–231. http://dx.doi.org/10.1016/j.virol.
2013.07.015.
Bzhalava, D., Mühr, L.S.A., Lagheden, C., Ekström, J., Forslund, O., Dillner, J., Hultin, E.,
2014. Deep sequencing extends the diversity of human papillomaviruses in human
skin. Sci. Rep. 4, 5807. http://dx.doi.org/10.1038/srep05807.
Casabonne, D., Michael, K.M., Waterboer, T., Pawlita, M., Forslund, O., Burk, R.D.,
Travis, R.C., Key, T.J., Newton, R., 2007. A prospective pilot study of antibodies
against human papillomaviruses and cutaneous squamous cell carcinoma nested in
the Oxford component of the European Prospective investigation into cancer and
Nutrition. Int. J. Cancer 121, 1862–1868. http://dx.doi.org/10.1002/ijc.22885.
Chen, Z., van Doorslaer, K., DeSalle, R., Wood, C.E., Kaplan, J.R., Wagner, J.D., Burk,
R.D., 2009. Genomic diversity and interspecies host infection of alpha12 Macaca
fascicularis papillomaviruses (MfPVs). Virology 393, 304–310. http://dx.doi.org/10.
1016/j.virol.2009.07.012.
Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T.J., Higgins, D.G., Thompson,
J.D., 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic
Acids Res. 31, 3497–3500.
Chouhy, D., Gorosito, M., Sánchez, A., Serra, E.C., Bergero, A., Fernandez Bussy, R., Giri,
A.A., 2010. New generic primer system targeting mucosal/genital and cutaneous
human papillomaviruses leads to the characterization of HPV 115, a novel Beta-pa-
pillomavirus species 3. Virology 397, 205–216. http://dx.doi.org/10.1016/j.virol.
2009.11.020.
Cornet, I., Bouvard, V., Campo, M.S., Thomas, M., Banks, L., Gissmann, L., Lamartine, J.,
Sylla, B.S., Accardi, R., Tommasino, M., 2012. Comparative analysis of transforming
properties of E6 and E7 from different beta human papillomavirus types. J. Virol. 86,
2366–2370. http://dx.doi.org/10.1128/JVI.06579-11.
de Jong-Tieben, L.M., Berkhout, R.J., Smits, H.L., Bouwes Bavinck, J.N., Vermeer, B.J.,
van der Woude, F.J., ter Schegget, J., 1995. High frequency of detection of epi-
dermodysplasia verruciformis-associated human papillomavirus DNA in biopsies
from malignant and premalignant skin lesions from renal transplant recipients. J.
Investig. Dermatol. 105, 367–371.
de Villiers, E.-M., Fauquet, C., Broker, T.R., Bernard, H.-U., zur Hausen, H., 2004.
Classification of papillomaviruses. Virology 324, 17–27. http://dx.doi.org/10.1016/
j.virol.2004.03.033.
Donà, M.G., Gheit, T., Vescio, M.F., Latini, A., Moretto, D., Benevolo, M., Cristaudo, A.,
Tommasino, M., Giuliani, M., 2016. Incidence, clearance and duration of cutaneous
beta and gamma human papillomavirus anal infection. J. Infect. 73, 380–383. http://
dx.doi.org/10.1016/j.jinf.2016.07.006.
Doorbar, J., Quint, W., Banks, L., Bravo, I.G., Stoler, M., Broker, T.R., Stanley, M.A., 2012.
The biology and life-cycle of human papillomaviruses. Vaccine 30 (Suppl 5), F55–70.
http://dx.doi.org/10.1016/j.vaccine.2012.06.083.
Dutta, S., Robitaille, A., Olivier, M., Rollison, D.E., Tommasino, M., Gheit, T., 2017.
Genome sequence of a novel human gammapapillomavirus isolated from skin.
Genome Announc. 5. http://dx.doi.org/10.1128/genomeA.00439-17.
Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy and high
throughput. Nucleic Acids Res. 32, 1792–1797. http://dx.doi.org/10.1093/nar/
gkh340.
Ekström, J., Bzhalava, D., Svenback, D., Forslund, O., Dillner, J., 2011. High throughput
sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions. Int. J.
Cancer 129, 2643–2650. http://dx.doi.org/10.1002/ijc.26204.
Ekström, J., Mühr, L.S.A., Bzhalava, D., Söderlund-Strand, A., Hultin, E., Nordin, P.,
Stenquist, B., Paoli, J., Forslund, O., Dillner, J., 2013. Diversity of human papillo-
maviruses in skin lesions. Virology 447, 300–311. http://dx.doi.org/10.1016/j.virol.
2013.09.010.
Forslund, O., Antonsson, A., Nordin, P., Stenquist, B., Hansson, B.G., 1999. A broad range
of human papillomavirus types detected with a general PCR method suitable for
analysis of cutaneous tumours and normal skin. J. Gen. Virol. 80 (Pt 9), 2437–2443.
http://dx.doi.org/10.1099/0022-1317-80-9-2437.
Forslund, O., Johansson, H., Madsen, K.G., Kofoed, K., 2013. The nasal mucosa contains a
large spectrum of human papillomavirus types from the betapapillomavirus and
gammapapillomavirus genera. J. Infect. Dis. 208, 1335–1341. http://dx.doi.org/10.
1093/infdis/jit326.
García-Pérez, R., Ibáñez, C., Godínez, J.M., Aréchiga, N., Garin, I., Pérez-Suárez, G., de
Paz, O., Juste, J., Echevarría, J.E., Bravo, I.G., 2014. Novel papillomaviruses in free-
ranging Iberian bats: no virus-host co-evolution, no strict host specificity, and hints
for recombination. Genome Biol. Evol. 6, 94–104. http://dx.doi.org/10.1093/gbe/
evt211.
Giuliano, A., Lazcano, E., Villa, L., Flores, R., Salmeron, J., Lee, J.-H., Papenfuss, M.,
Abrahamsen, M., Baggio, M., Silva, R., Quiterio, M., 2009. Circumcision and sexual
behavior: factors independently associated with human papillomavirus (HPV) de-
tection among men in The HIM study. Int. J. Cancer J. Int. Cancer 124, 1251–1257.
http://dx.doi.org/10.1002/ijc.24097.
Giuliano, A.R., Lazcano-Ponce, E., Villa, L.L., Flores, R., Salmeron, J., Lee, J.-H.,
Papenfuss, M.R., Abrahamsen, M., Jolles, E., Nielson, C.M., Baggio, M.L., Silva, R.,
Quiterio, M., 2008a. The human papillomavirus infection in men study: human pa-
pillomavirus prevalence and type distribution among men residing in Brazil, Mexico,
and the United States. Cancer Epidemiol. Biomark. Prev. 17, 2036–2043. http://dx.
doi.org/10.1158/1055-9965.EPI-08-0151.
Giuliano, A.R., Lee, J.-H., Fulp, W., Villa, L.L., Lazcano, E., Papenfuss, M.R., Abrahamsen,
M., Salmeron, J., Anic, G.M., Rollison, D.E., Smith, D., 2011. Incidence and clearance
of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377,
932–940. http://dx.doi.org/10.1016/S0140-6736(10)62342-2.
Giuliano, A.R., Tortolero-Luna, G., Ferrer, E., Burchell, A.N., de Sanjose, S., Kjaer, S.K.,
Muñoz, N., Schiffman, M., Bosch, F.X., 2008b. Epidemiology of human papilloma-
virus infection in men, in cancers other than cervical and in benign conditions.
Vaccine 26, K17–K28. http://dx.doi.org/10.1016/j.vaccine.2008.06.021.
Goon, P., Sonnex, C., Jani, P., Stanley, M., Sudhoff, H., 2008. Recurrent respiratory pa-
pillomatosis: an overview of current thinking and treatment. Eur. Arch.
Otorhinolaryngol. 265, 147–151. http://dx.doi.org/10.1007/s00405-007-0546-z.
Gottschling, M., Göker, M., Stamatakis, A., Bininda-Emonds, O.R.P., Nindl, I., Bravo, I.G.,
2011. Quantifying the phylodynamic forces driving papillomavirus evolution. Mol.
Biol. Evol. 28, 2101–2113. http://dx.doi.org/10.1093/molbev/msr030.
Grace, M., Munger, K., 2017. Proteomic analysis of the gamma human papillomavirus
type 197 E6 and E7 associated cellular proteins. Virology 500, 71–81. http://dx.doi.
org/10.1016/j.virol.2016.10.010.
Haedicke, J., Iftner, T., 2013. Human papillomaviruses and cancer. Radiother. Oncol.
108, 397–402. http://dx.doi.org/10.1016/j.radonc.2013.06.004.
Hampras, S.S., Giuliano, A.R., Lin, H.-Y., Fisher, K.J., Abrahamsen, M.E., McKay-Chopin,
S., Gheit, T., Tommasino, M., Rollison, D.E., 2015. Natural history of polyomaviruses
in men: the HPV infection in men (HIM) study. J. Infect. Dis. 211, 1437–1446. http://
dx.doi.org/10.1093/infdis/jiu626.
Hampras, S.S., Giuliano, A.R., Lin, H.-Y., Fisher, K.J., Abrahamsen, M.E., Sirak, B.A.,
Iannacone, M.R., Gheit, T., Tommasino, M., Rollison, D.E., 2014. Natural history of
cutaneous human papillomavirus (HPV) infection in men: the HIM study. PLoS One 9.
http://dx.doi.org/10.1371/journal.pone.0104843.
Hampras, S.S., Rollison, D.E., Giuliano, A.R., McKay-Chopin, S., Minoni, L., Sereday, K.,
Gheit, T., Tommasino, M., 2017. Prevalence and concordance of cutaneous beta
human papillomavirus infection at mucosal and cutaneous sites. J. Infect. Dis. 216,
92–96. http://dx.doi.org/10.1093/infdis/jix245.
Harwood, C.A., Surentheran, T., McGregor, J.M., Spink, P.J., Leigh, I.M., Breuer, J.,
Proby, C.M., 2000. Human papillomavirus infection and non-melanoma skin cancer
R.N. Brancaccio et al. Virology 520 (2018) 1–10
9
in immunosuppressed and immunocompetent individuals. J. Med. Virol. 61,
289–297.
Huang, X., Madan, A., 1999. CAP3: a DNA sequence assembly program. Genome Res. 9,
868–877.
Iannacone, M.R., Gheit, T., Pfister, H., Giuliano, A.R., Messina, J.L., Fenske, N.A.,
Cherpelis, B.S., Sondak, V.K., Roetzheim, R.G., Silling, S., Pawlita, M., Tommasino,
M., Rollison, D.E., 2014. Case-control study of genus-beta human papillomaviruses in
plucked eyebrow hairs and cutaneous squamous cell carcinoma. Int. J. Cancer 134,
2231–2244. http://dx.doi.org/10.1002/ijc.28552.
Iannacone, M.R., Gheit, T., Waterboer, T., Giuliano, A.R., Messina, J.L., Fenske, N.A.,
Cherpelis, B.S., Sondak, V.K., Roetzheim, R.G., Michael, K.M., Tommasino, M.,
Pawlita, M., Rollison, D.E., 2012. Case-control study of cutaneous human papillo-
maviruses in squamous cell carcinoma of the skin. Cancer Epidemiol. Biomark. 21,
1303–1313. http://dx.doi.org/10.1158/1055-9965.EPI-12-0032.
Iftner, A., Klug, S.J., Garbe, C., Blum, A., Stancu, A., Wilczynski, S.P., Iftner, T., 2003. The
prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of
nonimmunosuppressed individuals identifies high-risk genital types as possible risk
factors. Cancer Res. 63, 7515–7519.
Johansson, H., Bzhalava, D., Ekström, J., Hultin, E., Dillner, J., Forslund, O., 2013.
Metagenomic sequencing of “HPV-negative” condylomas detects novel putative HPV
types. Virology 440, 1–7. http://dx.doi.org/10.1016/j.virol.2013.01.023.
Käller, M., Ewels, P., 2016. MultiQC: summarize analysis results for multiple tools and
samples in a single report. Bioinformatics.
Karagas, M.R., Nelson, H.H., Sehr, P., Waterboer, T., Stukel, T.A., Andrew, A., Green,
A.C., Bavinck, J.N.B., Perry, A., Spencer, S., Rees, J.R., Mott, L.A., Pawlita, M., 2006.
Human papillomavirus infection and incidence of squamous cell and basal cell car-
cinomas of the skin. J. Natl. Cancer Inst. 98, 389–395. http://dx.doi.org/10.1093/
jnci/djj092.
Kocjan, B.J., Bzhalava, D., Forslund, O., Dillner, J., Poljak, M., 2015. Molecular methods
for identification and characterization of novel papillomaviruses. Clin. Microbiol.
Infect. 21, 808–816. http://dx.doi.org/10.1016/j.cmi.2015.05.011.
Krueger F., 2015. Trim Galore!: a wrapper tool around Cutadapt and FastQC to con-
sistently apply quality and adapter trimming to FastQ files.
Kumar, S., Stecher, G., Tamura, K., 2016. MEGA7: molecular evolutionary genetics
analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 33, 1870–1874. http://dx.
doi.org/10.1093/molbev/msw054.
Lunardi, M., de Alcântara, B.K., Otonel, R.A.A., Rodrigues, W.B., Alfieri, A.F., Alfieri,
A.A., 2013. Bovine papillomavirus type 13 DNA in equine sarcoids. J. Clin. Microbiol.
51, 2167–2171. http://dx.doi.org/10.1128/JCM.00371-13.
Mahé, F., Rognes, T., 2016. VSEARCH: a versatile open source tool for metagenomics.
PeerJ.
Matsen, F.A., Hoffman, N.G., Gallagher, A., Stamatakis, A., 2012. A format for phyloge-
netic placements. PLoS One 7, e31009. http://dx.doi.org/10.1371/journal.pone.
0031009.
Myers, G., Baker, G.M.C., Münger, K., Sverdrup, F., McBride, A. &.Bernard, H.U., 1997.
Alignments. In Human Papillomaviruses 1997. HPV Sequence Database II-L1–23–73.
Myers, G., Baker, G.M.C., Münger, K., Sverdrup, F., McBride, A. &.Bernard, H.U., 1996.
Alignments. In Human Papillomaviruses 1996. HPV Sequence Database II-L1–1–67.
Nei, Kumar, 2000. Molecular Evolution and Phylogenetics. Oxford University Press.
Nunes, E.M., Sudenga, S.L., Gheit, T., Tommasino, M., Baggio, M.L., Ferreira, S., Galan, L.,
Silva, R.C., Pierce Campbell, C.M., Lazcano-Ponce, E., Giuliano, A.R., Villa, L.L.,
Sichero, L., 2016. Diversity of beta-papillomavirus at anogenital and oral anatomic
sites of men: the HIM Study. Virology 495, 33–41. http://dx.doi.org/10.1016/j.virol.
2016.04.031.
Nyitray, A.G., Carvalho da Silva, R.J., Baggio, M.L., Lu, B., Smith, D., Abrahamsen, M.,
Papenfuss, M., Villa, L.L., Lazcano-Ponce, E., Giuliano, A.R., 2011. Age-specific
prevalence of and risk factors for anal human papillomavirus (HPV) among men who
have sex with women and men who have sex with men: the HPV in men (HIM) study.
J. Infect. Dis. 203, 49–57. http://dx.doi.org/10.1093/infdis/jiq021.
Ondov, B.D., Bergman, N.H., Phillippy, A.M., 2011. Interactive metagenomic visualiza-
tion in a Web browser. BMC Bioinform. 12, 385. http://dx.doi.org/10.1186/1471-
2105-12-385.
O’Neill, S.H., Newkirk, K.M., Anis, E.A., Brahmbhatt, R., Frank, L.A., Kania, S.A., 2011.
Detection of human papillomavirus DNA in feline premalignant and invasive squa-
mous cell carcinoma. Vet. Dermatol. 22, 68–74. http://dx.doi.org/10.1111/j.1365-
3164.2010.00912.x.
Orth, G., 2006. Genetics of epidermodysplasia verruciformis: insights into host defense
against papillomaviruses. Semin. Immunol. 18, 362–374. http://dx.doi.org/10.1016/
j.smim.2006.07.008.
Orth, G., Jablonska, S., Favre, M., Croissant, O., Jarzabek-Chorzelska, M., Rzesa, G., 1978.
Characterization of two types of human papillomaviruses in lesions of epidermo-
dysplasia verruciformis. Proc. Natl. Acad. Sci. USA 75, 1537–1541.
Pfister, H., 2003. Chapter 8: human papillomavirus and skin cancer. J. Natl. Cancer Inst.
Monogr. 52–56.
Pfister, H., Fuchs, P.G., Majewski, S., Jablonska, S., Pniewska, I., Malejczyk, M., 2003.
High prevalence of epidermodysplasia verruciformis-associated human papilloma-
virus DNA in actinic keratoses of the immunocompetent population. Arch. Dermatol.
Res. 295, 273–279. http://dx.doi.org/10.1007/s00403-003-0435-2.
Pierce Campbell, C.M., Gheit, T., Tommasino, M., Lin, H.-Y., Torres, B.N., Messina, J.L.,
Stoler, M.H., Rollison, D.E., Sirak, B.A., Abrahamsen, M., Carvalho da Silva, R.J.,
Sichero, L., Villa, L.L., Lazcano-Ponce, E., Giuliano, A.R., 2016. Cutaneous beta
human papillomaviruses and the development of male external genital lesions: a
case-control study nested within the HIM Study. Virology 497, 314–322. http://dx.
doi.org/10.1016/j.virol.2016.08.002.
Pierce Campbell, C.M., Messina, J.L., Stoler, M.H., Jukic, D.M., Tommasino, M., Gheit, T.,
Rollison, D.E., Sichero, L., Sirak, B.A., Ingles, D.J., Abrahamsen, M., Lu, B., Villa, L.L.,
Lazcano-Ponce, E., Giuliano, A.R., 2013. Cutaneous human papillomavirus types
detected on the surface of male external genital lesions: a case series within the HPV
Infection in Men Study. J. Clin. Virol. 58, 652–659. http://dx.doi.org/10.1016/j.jcv.
2013.10.011.
Rector, A., Van Ranst, M., 2013. Animal papillomaviruses. Virology 445, 213–223.
http://dx.doi.org/10.1016/j.virol.2013.05.007.
Smelov, V., Hanisch, R., McKay-Chopin, S., Sokolova, O., Eklund, C., Komyakov, B.,
Gheit, T., Tommasino, M., 2017. Prevalence of cutaneous beta and gamma human
papillomaviruses in the anal canal of men who have sex with women. Papillomavirus
Res. 3, 66–72. http://dx.doi.org/10.1016/j.pvr.2017.02.002.
Stamatakis, A., 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis
of large phylogenies. Bioinformatics 30, 1312–1313. http://dx.doi.org/10.1093/
bioinformatics/btu033.
Tommasino, M., 2017. The biology of beta human papillomaviruses. Virus Res. 231,
128–138. http://dx.doi.org/10.1016/j.virusres.2016.11.013.
Tommasino, M., 2014. The human papillomavirus family and its role in carcinogenesis.
Semin. Cancer Biol. 26, 13–21. http://dx.doi.org/10.1016/j.semcancer.2013.11.002.
Trewby, H., Ayele, G., Borzacchiello, G., Brandt, S., Campo, M.S., Del Fava, C., Marais, J.,
Leonardi, L., Vanselow, B., Biek, R., Nasir, L., 2014. Analysis of the long control
region of bovine papillomavirus type 1 associated with sarcoids in equine hosts in-
dicates multiple cross-species transmission events and phylogeographical structure. J.
Gen. Virol. 95, 2748–2756. http://dx.doi.org/10.1099/vir.0.066589-0.
Van Doorslaer, K., Li, Z., Xirasagar, S., Maes, P., Kaminsky, D., Liou, D., Sun, Q., Kaur, R.,
Huyen, Y., McBride, A.A., 2017. The Papillomavirus Episteme: a major update to the
papillomavirus sequence database. Nucleic Acids Res. 45, D499–D506. http://dx.doi.
org/10.1093/nar/gkw879.
Van Doorslaer, K., Tan, Q., Xirasagar, S., Bandaru, S., Gopalan, V., Mohamoud, Y., Huyen,
Y., McBride, A.A., 2013. The papillomavirus Episteme: a central resource for pa-
pillomavirus sequence data and analysis. Nucleic Acids Res. 41, D571–D578. http://
dx.doi.org/10.1093/nar/gks984.
Viarisio, D., Müller-Decker, K., Zanna, P., Kloz, U., Aengeneyndt, B., Accardi, R.,
Flechtenmacher, C., Gissmann, L., Tommasino, M., 2016. Novel ß-HPV49 transgenic
mouse model of upper digestive tract cancer. Cancer Res. 76, 4216–4225. http://dx.
doi.org/10.1158/0008-5472.CAN-16-0370.
Waterboer, T., Abeni, D., Sampogna, F., Rother, A., Masini, C., Sehr, P., Michael, K.M.,
Pawlita, M., 2008. Serological association of beta and gamma human papilloma-
viruses with squamous cell carcinoma of the skin. Br. J. Dermatol. 159, 457–459.
http://dx.doi.org/10.1111/j.1365-2133.2008.08621.x.
R.N. Brancaccio et al. Virology 520 (2018) 1–10
10
